Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136836 | 0.82 | KDM4E (0.66) | ALDH1A1GAALMNAHPGDKDM4E | |
| SCHEMBL6311629 | 0.80 | MAPT (0.66) | ALDH1A1LMNAHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL5286439 | 0.78 | SMN1; SMN2 (0.48) | ALDH1A1GAALMNAHPGDSMN1; SMN2 | |
| SCHEMBL14087050 | 0.78 | KDM4E (0.67) | ALDH1A1GAALMNAHPGDKDM4E | |
| SCHEMBL5286547 | 0.77 | HDAC1 (0.54) | ALDH1A1GAALMNAHPGDKDM4E | |
| SCHEMBL1422234 | 0.77 | LMNA (0.74) | ALDH1A1GAALMNAHPGDKDM4E | |
| SCHEMBL5282505 | 0.77 | NOTUM (0.51) | ALDH1A1GAALMNAHPGDSMN1; SMN2 | |
| SCHEMBL9832171 | 0.75 | KDM4E (0.67) | ALDH1A1GAALMNAHPGDKDM4E | |
| SCHEMBL31225490 | 0.75 | SMN1; SMN2 (0.55) | ALDH1A1GAALMNASMN1; SMN2HTT | |
| SCHEMBL5717705 | 0.75 | KDM4E (0.71) | ALDH1A1GAALMNAHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | ALDH1A1 2972/4885GAA 496/4885LMNA 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.